Literature DB >> 2844334

Sensitivity of cytomegalovirus to intravenous foscarnet treatment.

A Akesson-Johansson1, J O Lernestedt, O Ringdén, B Lönnqvist, B Wahren.   

Abstract

Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients. Thirteen patients responded to foscarnet by cessation of CMV secretion. The in vitro sensitivity to foscarnet of the CMV isolates from non-responders before, during and after foscarnet treatment was similar to that of viral isolates from responders before or during foscarnet treatment and also to CMV isolates from non-treated patients, with mean in vitro IC50 values of 239-294 microM of foscarnet. Thus, there was no evidence of increased resistance of the CMV isolates obtained after foscarnet treatment. A higher total foscarnet dose appeared to favor response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2844334

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.

Authors:  D T Dieterich; M A Poles; E A Lew; S Martin-Munley; J Johnson; D Nix; M J Faust
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 2.  Acquisition of cytomegalovirus infection: an update.

Authors:  B A Forbes
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

Review 3.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

4.  Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.

Authors:  M A Jacobson; J J O'Donnell; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 5.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.